RCS - Angle PLC - Potential utility in precision oncology

AngleAnnouncement

22/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240122:nRSV3600Aa&default-theme=true

RNS Number : 3600A  Angle PLC  22 January 2024

 For immediate release  22 January 2024

 

ANGLE plc ("the Company")

 

REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST HIGHLIGHTS
POTENTIAL UTILITY IN PRECISION ONCOLOGY

 

Paper published in the journal "Current Issues in Molecular Biology" special
issue: advanced solutions for cancer therapy

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology, is pleased to announce the
publication of a peer-reviewed paper in a special issue of the journal -
"Current Issues in Molecular Biology" Special Issue: Advanced Solutions for
Cancer Therapy.

 

ANGLE recently announced breakthrough data from a newly established workflow
for real-time parallel Next Generation Sequencing (NGS) DNA analysis of both
ctDNA (fragments of DNA released mainly by dying cells) and CTCs (living
cancer cells) from a single tube of patient blood, using a pan-cancer panel
run on an Illumina NGS system. This peer-reviewed article brings together
supporting evidence for the additional and complementary information that can
be obtained from CTCs using the Parsortix(®) system, demonstrating the value
of a dual analyte approach for both CTCs and ctDNA.

 

The review article details research from multiple independent, leading cancer
centres, such as The University of Athens, Greece, University Medical Center
Hamburg-Eppendorf, Germany, Fondazione IRCCS Istituto Nazionale dei Tumori,
Italy, the Health Research Institute of Santiago (IDIS), Spain and Edith Cowan
University, Australia. The benefits of utilising the Parsortix system for
downstream molecular analysis is showcased across these cancer centres in
various cancer types including non-small cell lung cancer, triple negative
breast cancer, head and neck cancer, colorectal cancer, and melanoma,
highlighting the wide utility of the Parsortix system.

 

In support of ANGLE's breakthrough data, DNA variants were identified in some
studies that were exclusive to CTCs, as compared to ctDNA, and the combined
molecular analysis of CTCs and ctDNA in a research setting increased the
number of patients identified with a potentially actionable biomarker,
providing a more comprehensive gene variant profile. This enhanced gene
variant profile has the potential, subject to further study, to inform on
prognosis, treatment selection, monitoring of treatment resistance and disease
relapse.

 

The Parsortix system is identified as the optimal technology for this purpose
as, with Parsortix label-free microfluidic isolation, all phenotypes of CTCs
can be harvested intact and undamaged providing easily accessible samples for
molecular analysis with low white blood cell background.

 

The review article contextualises these findings within the field of liquid
biopsies, highlighting the shift in understanding that CTCs and ctDNA can
provide complementary and additive information. Harvested CTCs also have the
added advantage in that they can undergo RNA, protein, and morphological
analysis, thus combining genotype with phenotype to give a comprehensive
biomarker profile. These recent advances in molecular oncology, combined with
broad phenotyping including protein expression and analysis of methylation
patterns are driving the implementation of precision oncology, with the aim of
improving patient care.

 

The peer-reviewed journal article entitled "Molecular Profiling of Circulating
Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single
Blood Sample Utilising the Parsortix System" is available through Open Access
and is available on the Company's website: www.angleplc.com/publications/
(http://www.angleplc.com/publications/)

 

ANGLE Chief Scientific Officer, Karen Miller, commented:

"As the revolution in 'omics' data evolves, the importance of CTCs to extract
genomic and phenotypic profiling information is becoming increasingly evident,
providing valuable and potentially actionable data that, subject to further
study, may be used to guide patient management decisions in a way that is not
possible using only ctDNA."

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) diagnostic solutions for use in research, drug development
and clinical oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting technology known as
the Parsortix(®) PC1 System enables complete downstream analysis of the
sample including whole cell imaging and proteomic analysis and full genomic
and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories.  Services include custom made assay development
and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUACGUPCGMB